Some British scientists succeeded in uncovering why some breast cancer patients who fail therapy. It turned out that the cause is too much gene called FGFR1 who do not respond to drug therapy Tamoxifen.
Tamoxifen is a drug used to prevent breast cancer recurrence. Unfortunately, one third of patients did not give a positive response to the results of this therapy. In the journal Cancer Research, the scientists managed to write them off FGFR1 gene that tamoxifen could work.
Experts say, when FGFR1 was stopped, hormone-based therapies such as tamoxifen drug could return to work to destroy cancer cells. It is believed to help save the lives of thousands of patients each year.
Dr Nick Turner, head researcher said one of the 10 breast cancer patients have a number of genes that are too high FGFR1. "There are several types of drugs developed to stop the work FGFR1 and clinical studies conducted to determine whether this drug could fight cancer with so many copies of the gene," he said.
Tamoxifen works by inhibiting female sex hormone, estrogen, which fueled the growth of tumors
source: Kompas.com
No comments:
Post a Comment